Demary Winfried, Schwenke Holger, Rockwitz Karin, Kästner Peter, Liebhaber Anke, Schoo Ulrich, Hübner Georg, Pichlmeier Uwe, Guimbal-Schmolck Cécile, Müller-Ladner Ulf
Private practice, Hildesheim, Germany.
Private practice, Dresden, Germany.
Patient Prefer Adherence. 2014 Aug 6;8:1061-71. doi: 10.2147/PPA.S64111. eCollection 2014.
This multicenter, randomized, crossover study compared preference, ease of use, acceptability, satisfaction, and safety of repeated subcutaneous (SC) self-administrations with prefilled pens and prefilled syringes delivering methotrexate (MTX), in patients with rheumatoid arthritis (RA).
The study (ClinicalTrials.gov number NCT01793259) enrolled 120 patients requiring initiation or intensification of MTX therapy for RA. Patients were randomized to receive the test drug, a prefilled pen (Metex(®) PEN/Metoject(®) PEN), or the reference drug, a prefilled syringe (Metex(®)/Metoject(®)), at doses of 15, 17.5, or 20 mg MTX SC once a week for 3 weeks. This was followed by receipt of the reference drug (prefilled syringe) or the test drug (prefilled pen) in a crossover design, with each patient serving as his/her own control. Questionnaires regarding patient preference, the Self-Injection Assessment Questionnaire (SIAQ), and diaries regarding local tolerability were used to document outcomes.
Overall patient preference for the MTX prefilled pen was 75% (P<0.0001). In a six-item questionnaire, 73% to 76% of the patients preferred the prefilled pen in relation to use, acceptability, and satisfaction, and 67% of the patients confirmed that it did not take much effort to overcome SC self-injection with the pen. The SIAQ showed no clinical differences, in any domain scores, between both devices. Overall patient attitude towards self-injection at baseline was positive, as was patient experience with both devices during the study. As well, 92% of physicians and study nurses indicated that they would recommend the MTX prefilled pen to patients for future MTX treatment. The formulations were generally well tolerated.
SC self-injection of MTX with a prefilled pen was generally preferred, by patients with RA, over a prefilled syringe with regard to use, acceptability, and satisfaction. This is supported by the strong appreciation of their attending study nurses and physicians, for its convenience.
本多中心、随机、交叉研究比较了类风湿关节炎(RA)患者使用预填充笔和预填充注射器重复皮下(SC)自我注射甲氨蝶呤(MTX)时的偏好、易用性、可接受性、满意度和安全性。
该研究(ClinicalTrials.gov编号NCT01793259)纳入了120例需要开始或强化MTX治疗RA的患者。患者被随机分配接受试验药物(预填充笔(Metex(®) PEN/Metoject(®) PEN))或参比药物(预填充注射器(Metex(®)/Metoject(®))),剂量为15、17.5或20mg MTX,每周皮下注射一次,共3周。之后采用交叉设计,患者接受参比药物(预填充注射器)或试验药物(预填充笔),每位患者作为自身对照。使用关于患者偏好的问卷、自我注射评估问卷(SIAQ)以及关于局部耐受性的日记来记录结果。
患者对MTX预填充笔的总体偏好率为75%(P<0.0001)。在一份六项问卷中,73%至76%的患者在使用、可接受性和满意度方面更喜欢预填充笔,67%的患者确认使用笔进行皮下自我注射并不费力。SIAQ显示,在任何领域得分上,两种器械之间均无临床差异。患者在基线时对自我注射的总体态度是积极的,在研究期间对两种器械的体验也是如此。此外,92%的医生和研究护士表示,他们会向患者推荐MTX预填充笔用于未来的MTX治疗。这些制剂总体耐受性良好。
对于RA患者,在使用、可接受性和满意度方面,使用预填充笔进行MTX皮下自我注射通常比预填充注射器更受青睐。其便利性得到了参与研究护士和医生的高度认可,这也为此提供了支持。